Canertinib is an orally bio-available EGFR inhibitor with potential anti-neoplastic and radio-sensitizing activities. It has IC50 values of 1.5 nM and 9.0 nM against EGFR and ErbB2 respectively, with no activity against PDGFR, FGFR, InsR, PKC, or CDK1/2/4.
Product Details
| Alternative Name: | PD-183805, CI-1033, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide |
| |
| Formula: | C24H25ClFN5O3 |
| |
| MW: | 485.9 |
| |
| CAS: | 267243-28-7 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | Yellow powder. |
| |
| Solubility: | Soluble in DMSO (2mg/ml) or ethanol (<9mg/ml). |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
